Successful treatment of two consecutive cases of pulmonary pleomorphic carcinoma with platinum chemotherapy

DAISUKE KATO¹, YUICHI CHIHARA¹, TOMOYUKI SHIRASE², TAMAKI TAKAHASHI¹, KEN-ICHI TAKAHASHI¹ and NAOKI SAKAI¹

¹Respiratory Disease Center and ²Department of Pathology, Otsu Red Cross Hospital, Otsu, Shiga 520-8511, Japan

Received October 25, 2014; Accepted August 5, 2015

DOI: 10.3892/ol.2015.3678

Abstract. Pulmonary pleomorphic carcinoma (PPC) is a rare pulmonary malignant tumor that has a more aggressive clinical course and a poorer prognosis compared with non-small cell lung cancer (NSCLC) due to its resistance to chemotherapy and radiotherapy. In patients with advanced or relapsed PPC, it has been reported that the response rate to chemotherapy regimens known to be effective in patients with NSCLC is only 0-17%. The present study reports the cases of two consecutive patients with advanced PPC who exhibited marked responses to chemotherapy with carboplatin plus paclitaxel chemotherapy and long-term survival without tumor progression. This suggests that carboplatin plus paclitaxel chemotherapy is a good option for the treatment of advanced PPC.

Introduction

Pulmonary pleomorphic carcinoma (PPC) is a rare primary malignant tumor in which carcinomatous and sarcomatous elements occur. The occurrence of the disease is extremely rare, accounting for only 0.1-0.4% of all reported malignant lung tumors (1-4). Patients with PPC are reported to be predominantly male smokers with a mean age of 66 years (5-8). PPC generally exhibits an aggressive clinical course, and has a tendency to grow rapidly and invade adjacent structures in the early stage. The recurrence after surgical treatment is common, and systemic metastases are frequently observed in patients with PPC (8). The prognosis of PPC is significantly worse than the majority of other subsets of non-small cell lung cancer (NSCLC) due to its poorer response to chemotherapy and radiotherapy. The response rate to chemotherapy regimens commonly used for NSCLC is in the range of 0–17% (2,9) and the median survival reported for patients with PPC was 5-10 months (1,2,9). The present study reports two cases of advanced PPC that were successfully treated with carboplatin plus paclitaxel chemotherapy and/or radiotherapy.

Case report

Case 1. A 66-year-old male was admitted to the Otsu Red Cross Hospital (Otsu, Shiga, Japan) in May 2013, due to a persistent cough and dyspnea that had persisted for 10 days. The patient had previously undergone a surgical resection of the colon due to a gastrointestinal stromal tumor. The patient had also smoked two packs of cigarettes per day for 37 years. A performance status score of 1, according to the Eastern Cooperative Oncology Group (ECOG) scale (10), was recorded. Computed tomography (CT) of the chest showed a large tumor, measuring 100x80 mm, in the right lower lobe of the lung, with pleural effusion. An ultrasonography-guided percutaneous lung biopsy was performed, and the tumor specimen consisted of epithelioid and sarcomatous components (Fig. 1A). On immunohistochemical staining, pankeratin was diffusely positive in the epithelioid and sarcomatous components (Fig. 1B). The patient was diagnosed with PPC based on the morphological findings of the tumor cells admixed with sarcomatoid and epithelioid cells. There was no evidence of metastasis to the other organs, corresponding to a diagnosis of clinical stage IV (cT4N0M1a) in the TNM classification (11). Subsequent to a thoracentesis, systemic chemotherapy was administered consisting of carboplatin [area under the curve (AUC), 6] and paclitaxel (200 mg/m²) on the first day by intravenous administration every three weeks for four cycles. Following chemotherapy, the tumor was markedly reduced in size from 100x80 to 75x22 mm, with disappearance of pleural effusions on chest CT (Fig. 2A and B), indicating that a partial remission was achieved. Mild anemia (grade 2), moderate leukopenia (grade 3) and peripheral neuropathy (grade 3) developed during carboplatin plus paclitaxel chemotherapy, but were not accompanied by any infectious complications, and the patient's performance status improved from 1 to 0. The patient is currently alive with no tumor progression at 12 months post-chemotherapy.

Case 2. A 69-year-old male presented with abnormal shadows in the left middle lung field on a chest X-ray that was taken during a routine health check, and was admitted to the Otsu
Red Cross Hospital (Otsu, Shiga, Japan) in September 2012. The patient had a history of chronic obstructive pulmonary disease and was a smoker of one pack of cigarettes per day for the last 50 years. The ECOG performance status was 0. CT of the chest showed a lung mass, measuring 54x42 mm, in the left upper lobe, with enlargement of the ipsilateral hilar
lymph node in addition to emphysema. A transbronchial lung biopsy was performed, and the tumor cells exhibited a biphasic appearance, with epithelioid and spindle cell sarcomatous components (Fig. 3A). Antibodies against pankeratin were reactive in the epithelioid and spindle cell sarcomatous components (Fig. 3B), while antibodies against c-kit, carcinoembryonic antigen, thyroid transcription factor-1 and D2-40 were non-reactive. As a result, a diagnosis of PPC was made. 18F-fluorodeoxyglucose positron emission tomography revealed high uptake in the left lung tumor, ipsilateral hilar lymph node and contralateral mediastinal lymph nodes. There was no evidence of metastasis to the other organs, corresponding to a diagnosis of clinical stage III B (cT2aN3M0) in the TNM classification (11). The patient received carboplatin (AUC, 6) and paclitaxel (200 mg/m²) every three weeks for three cycles plus concurrent radiation therapy (60 Gy in 30 daily fractions) over a period of 6 weeks. A marked reduction in tumor size from 54x42 to 18x19 mm was noted following chemoradiotherapy (Fig. 4A and B), and a partial remission was achieved. During chemoradiotherapy, tolerable myelosuppression and neuropathy (grade 2 anemia and leukopenia, and grade 3 neutropenia and peripheral neuropathy) occurred. The patient is currently alive with no tumor progression at 21 months post-chemoradiotherapy. The two patients gave written informed consent to participate in this clinical study.

Discussion

PPC was first introduced in the third edition of the World Health Organization (WHO) classifications (12), grouped under the category of carcinomas with pleomorphic, sarcomatoid or sarcomatous elements. PPC is defined as a poorly-differentiated NSCLC with ≥10% giant and/or spindle cell components, or as a carcinoma comprised completely of giant and spindle cells in the new WHO Classification of Lung Cancers (13). PPC is believed to be more aggressive and exhibit a poorer prognosis than ordinary lung carcinomas (1,3,14). There are few studies with regard to the chemotherapy of PPC, and its clinical and pathological characteristics therefore remain unclear. In patients with advanced or relapsed PPC, the response rate to chemotherapy regimens that are known to be effective in patients with NSCLC is only 0-17% (2,9). A previous study reported the cases of two patients with advanced PPC who showed a partial remission to chemotherapy with doxorubicin, ifosfamide and dacarbazine. However these two patients experienced early relapses following cessation of this combination chemotherapy (15).

The chemosensitivity of surgically-resected PPC has been evaluated using the histoculture drug response assay in a previous study (16). The study demonstrated that taxanes showed a good sensitivity in PPC. Therefore, it was conceivable that PPC may respond to chemotherapy that included taxanes. In the present study, two consecutive patients showed marked responses to carboplatin plus paclitaxel chemotherapy and/or radiotherapy, and experienced long-term survival without tumor progression following therapy. In patients with PPC, it has also been reported that a tumor size of ≥5 cm, a clinical stage of greater than stage I and lymph node involvement confer a significantly poor prognosis (5). Although the two present patients exhibited these poor prognostic factors, they experienced long-term survival. The present results suggest that carboplatin plus paclitaxel chemotherapy and/or radiotherapy may have an important role in the treatment of patients with advanced PPC.

In conclusion, the present study reported two cases in which carboplatin and paclitaxel were markedly effective for PPC. The success with these two cases further suggests that a multi-institutional study to evaluate treatment with carboplatin and paclitaxel is warranted.

References